3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Phase 1
2
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER_GOV
1
OTHER
1
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
28
Gynecologic
22
Other solid neoplasm
14
Tumor-Agnostic
13
Genitourinary
12
Gastrointestinal
11
Thoracic
7
Head & Neck
5
Sarcoma
4
Lymphoid
4
Classical hematology
3
NET
2
Endocrine
2
Dermatologic
2
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
CNS
1
Conditions
Neuroendocrine Tumors
2
Thymoma
1
Mesothelioma
1
Interventions
Everolimus
10
lutetium Lu 177 dotatate
7
Magnetic Resonance Spectroscopy
7
pasireotide
4
Specimen Handling
3
Positron Emission Tomography Computed Tomography
3
Nivolumab
3
Ga(III)-DOTATOC
3
Fluorodeoxyglucose F18
3
(177)Lu-DOTA-EB-TATE
3
olaparib
2
gallium Ga 68 dotatate
2
amino-acid, glucose, and electrolyte solution
2
Temozolomide
2
Lutetium-177
2
Ipilimumab
2
FAPI-46
2
veliparib
1
vandetanib
1
trifluridine tipiracil drug combination
1
toripalimab
1
tislelizumab
1
talazoparib
1
surufatinib
1
romidepsin
1
peposertib
1
pembrolizumab
1
pelcitoclax
1
pegfilgrastim
1
lanreotide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1
×
olaparib
×
NET
×
Clear all
NCT04375267
2026-04-14
LuPARP
Vastra Gotaland Region
Phase 1
Completed
18 enrolled
NCT05870423
2025-06-05
PRRT-PARPi
Erasmus Medical Center
Phase 1
Recruiting
24 enrolled